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Abstract
Currently, there are no reported genetic predictors of motor symptom progression in Parkinson’s disease (PD). In familial PD,
disease severity is associated with higher a-synuclein (SNCA) expression levels, and in postmortem studies expression varies
with SNCA genetic variants. Furthermore, SNCA is a well-known risk factor for PD occurrence. We recruited Parkinson’s
patients from the communities of three central California counties to investigate the influence of SNCA genetic variants on
motor symptom progression in idiopathic PD. We repeatedly assessed this cohort of patients over an average of 5.1 years
for motor symptom changes employing the Unified Parkinson’s Disease Rating Scale (UPDRS). Of 363 population-based
incident PD cases diagnosed less than 3 years from baseline assessment, 242 cases were successfully re-contacted and 233
were re-examined at least once. Of subjects lost to follow-up, 69% were due to death. Adjusting for covariates, risk of faster
decline of motor function as measured by annual increase in motor UPDRS exam score was increased 4-fold in carriers of the
REP1 263bp promoter variant (OR 4.03, 95%CI:1.57–10.4). Our data also suggest a contribution to increased risk by the G-
allele for rs356165 (OR 1.66; 95%CI:0.96–2.88), and we observed a strong trend across categories when both genetic variants
were considered (p for trend =0.002). Our population-based study has demonstrated that SNCA variants are strong
predictors of faster motor decline in idiopathic PD. SNCA may be a promising target for therapies and may help identify
patients who will benefit most from early interventions. This is the first study to link SNCA to motor symptom decline in
a longitudinal progression study.
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Introduction
Parkinson’s disease (PD) is a neurological condition character-
ized by progressive functional decline in motor function leading to
disability and loss of quality of life [1]. Rate and severity of decline
vary among patients but in all cases deterioration is inevitable as
there are no current disease-modifying therapies that prevent or
slow the neurodegenerative processes that cause PD [2]. More
than a decade ago, clinical predictors of motor symptom
progression were identified [3] including postural instability/gait
disturbances, low Activities of Daily Living score, and dementia
early in PD; since then only age at onset of symptoms has been
added to this list [4]. One possible reason for the continuing
paucity of information on risk factors for motor progression is that
most PD patient cohorts with longitudinal data are comprised of
non-representative groups of patients such as volunteers for clinical
trials or referral patients at tertiary care centers. Such cohorts
typically contain little information on non-clinical factors thereby
presenting challenges for the identification of risk factors for
progression beyond the most common clinical characteristics (such
as age of symptom onset or motor subtype). Also, larger, mostly
record-based studies are limited by the available outcomes (usually
only comorbidities and mortality), typically lack of systematic
motor symptom assessment, and generally have not collected
lifestyle, environmental, or genetic risk factor data.
There are only a few population-based (community) studies
publishing on motor progression using multiple motor symptom
assessments over time, i.e., with longitudinally followed PD
patients [3,5,6]. While one study [6] enrolled incident cases, two
others [3,5] enrolled prevalent cases with long (.5 years) mean
duration of disease prior to baseline assessment thereby preventing
observation of the early stages of disease progression and therefore
perhaps overlooking critical factors involved in faster motor
symptom decline [7]. Furthermore, these previous longitudinal
studies started with fewer than 250 PD cases at baseline and all
had only 50–60% of subjects remaining for follow-up assessment
rendering them under-powered to examine all but the most
common predictors of motor decline.
Recent publications have called for prospective cohorts of PD
patients assembled early in disease [8] and clinico-genetic studies
[9] to help unlock the heterogeneity of PD and its progression.
Identifying genetic predictors may aid clinical decision-making,
help target patients for treatment trials, and improve our
understanding of disease processes. Thus far, genetic predictors
of motor decline have not been reported in longitudinally followed
incident PD cohorts, largely due to the limited number of such
cohorts with biosamples.
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risk of PD occurrence and genetic variation in the a-synuclein
(SNCA) gene [10–16]. SNCA has been a candidate gene for
idiopathic PD ever since the localization of the PARK1 loci to the
SNCA gene region in a large Italian kindred [17] and identification
of SNCA protein in Lewy bodies [18]. By far the most frequently
investigated genetic variant in SNCA is the microsatellite D4S3481
(SNCA-Rep1), located in the promoter, approximately 10 kb
upstream of SNCA, and first reported in the Alzheimer literature
[19]. While the first PD association study of SNCA-Rep1 [20] did
not observed a difference in allele distribution between PD patients
with a family history of PD and unaffected controls, it did find
a significant difference in allele distribution between PD patients
without a family history and unaffected controls. Two following
studies [21,22] observed a higher frequency of the 263 base pair
(bp) repeat allele in PD cases compared with healthy controls. In
2006, a meta-analysis of 11 study populations including over 5000
subjects provided strong evidence that the 263bp allele was more
frequent in cases increasing risk of PD (OR 1.43, 95% CI 1.22–
1.69, dominant model) and that the 259bp allele was more
frequent in controls decreasing risk of PD (OR=0.85, 95% CI
0.76–0.96, dominant model); while the 261bp allele did not differ
between PD cases and unaffected controls [10].
The linkage disequilibrium (LD) structure of SNCA suggests two
distinct haplotype blocks, one covering an area from the 59 end of
the gene (the region of SNCA-Rep1) to exon 4 and the other
covering from intron 4 to the 39 region of the gene [23,24]. While
many studies have investigated haplotypes containing the SNCA-
Rep1 promoter variant in conjunction with other single nucleotide
polymorphisms (SNPs) in the 59 region [10,21,24–32], use of
promoter SNPs in place of or in addition to SNCA-Rep1 has not
yet demonstrated improvement in risk estimation [10,32]. In the
39 region of SNCA most studies have investigated either rs356165
(first reported in Pals et al [26]; meta-analysis of 11 Caucasian
studies, OR 1.32, 95%CI: 1.23–1.42 [33]) or rs356219 (first
reported in Mueller et al [28]; meta-analysis of 18 Caucasian
studies, OR=1.28, 95%CI: 1.23–1.32 [33]). These two SNPs are
in very high LD (D’=1, r ˆ2=0.962, LOD=26.27 [34]) and either
one uniquely identifies the two most common 39 region haplotypes
as reported in Pankratz et al [35]. In contrast, correlation between
SNCA-Rep1 and rs356219 was found to be very low (r ˆ2=0.09) in
a recent large study [36] supporting the hypothesis of two regions
contributing to genetic risk of PD [37]. However, others
hypothesized that the SNCA-Rep1 263bp allele arose on the
haplotype background defined by the ‘G’ allele at rs356165 (or
rs356219) thereby indicating a single genetic effect [23].
While findings from studies investigating SNCA 59 and 39 region
genetic variants and age of onset of PD have been inconsistent
[10,16,30,31,35,38–43], there is data supporting biologic effects
for genetic variants in SNCA possibly modifying the PD phenotype.
Both SNCA-Rep1 [44,45] and 39 region alleles [46] have been
associated with increased gene expression; and 39 region risk
alleles have been reported to correlate with higher plasma alpha-
synuclein levels in PD patients [36]. Gene duplication [47,48] and
triplication [49,50] in familial PD have been linked to increased
mRNA expression levels [50–52] and to severity of disease [53,54].
Furthermore, the a-synuclein protein product, a major component
of Lewy bodies [18], likely contributes significantly to PD
neurodegeneration and consequently to motor symptom decline.
Therefore, in this large, longitudinally followed population-based
incident PD cohort we investigate, for the first time, whether
genetic variation in the SNCA gene, a known risk factor for PD
onset, contributes to PD motor symptom decline.
Methods
This study was approved by the human subjects committee of
the University of Los Angeles (UCLA). Subjects participated in the
study after written informed consent was obtained; prospective
participants and their families/guardians were asked to discuss the
consent documents; consent on behalf of participants deemed
incapable of consenting was obtained from those determined to be
legal proxies for the patient.
Study Population
This longitudinal patient cohort is derived from a case-control
study that enrolled PD patients and population-based controls
between 2001 and 2007 in Central California. Recruitment
methods [55,56] and case definition criteria [57] have been
described in detail elsewhere. Briefly, of 1,167 PD patients initially
invited, 604 did not meet eligibility criteria primarily due to having
a first physician diagnosis of PD more than 3 years prior to
baseline. Of the 563 eligible patients, 473(84%) were examined by
our movement disorder specialists (JB and YB) at least once; 104
did not meet published criteria for idiopathic PD [58] and 6 had
incomplete data. The remaining 363 idiopathic PD patients
compose the PD cohort that is the basis of this longitudinal follow-
up investigation.
At first re-contact 83(22.9%) patients were deceased, 25(6.9%)
withdrew, 9(2.5%) could not be found, and 4(1.1%) were too ill to
participate. For follow-up, 242(66.6%) cases were successfully re-
contacted with 6 patients participating by mail/phone only (no in-
person follow-up exam and therefore not contributing to this
analysis) and 3 patients re-classified by us during follow-up as not
having idiopathic PD. Of 233 patients re-examined and confirmed
to have idiopathic PD, 178(76.4%) were seen twice and 55 were
seen only once during follow-up (21 were deceased prior to the
second exam and 14 are still pending second exams, 8 were too ill
to participate, 4 could not be not located, 3 withdrew, and 5
participated by mail/phone only). For these analyses, 232 of the
233 patients with at least one follow-up had SNCA genotype data
available. All patients completed an interview to collect de-
mographic and risk factor data; and provided blood samples for
DNA.
Assessment of PD Motor Symptom Progression
Baseline and follow-up Unified Parkinson’s Disease Rating
Scale (UPDRS) [59] exams were performed at a clinic near the
patient’s residence or at that residence if the patient was unable to
travel. Patients were examined off PD medications (i.e. overnight
medication withdrawal prior to exam) whenever possible (82% of
patients were off medication for baseline exam, 80% for follow-up
exams). For patients and time points without an off exam, we
estimated the off exam score by adding to the patient’s on exam
score the difference of the study population’s mean off- and mean
on-scores. At each exam 6% of PD patients were unable to
perform one or more motor UPDRS exam items (e.g. patients
unable to walk due to a missing lower limb); we replaced missing
exam items either assuming no change from baseline to follow-up
for patients with available baseline data or assuming the
population mean for patients with neither baseline nor follow-up
values available, an approach likely to bias our estimates towards
the null and therefore a conservative approach.
Annual rate of change in UPDRS motor score was calculated as
the difference of the last follow-up and the baseline motor scores
divided by the interval of time (in years) between exams. We did
not assume a linear association between the SNCA genetic variants
and rates of motor progression since our analyses would be too
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points/year change in motor UPDRS has been reported for early
untreated PD patients in placebo arms of clinical trials [2] and is
considered a clinically relevant change when assessing improve-
ment due to treatment [60], we defined ‘‘fast’’ motor symptom
decline as a 5 or more point increase in the annual rate of change.
Determination of SNCA Variants
SNCA genetic variants were genotyped according to previously
published methods [30,61]. The SNCA microsatellite Rep1
(D4S3481) was genotyped using fluorescent-labeled forward and
reverse primers designed to the a-synuclein promoter locus
(accession no. U46895), Fam59-CCT GGC ATA TTT GAT
TGC AA-39 and 59-GAC TGG CCC AAG ATT AAC CA-39.
Detection and analysis was performed on an ABI 3730 DNA
Analyzer (Applied Biosystems, Inc.) with Genemapper software.
SNCA rs356165 in the 39 untranslated region (39UTR) was
genotyped on an ABI 7900 Genome Analyzer using ABI
TaqmanH chemistry.
Statistical Analysis
Hardy-Weinberg equilibrium was assessed for each variant
using Mendel 10.0 [62]. Logistic regression analyses (SAS 9.1.3,
SAS Institute, Cary, NC) were employed to estimate odds ratios
(OR) and 95% confidence intervals (CI) adjusting for age at PD
diagnosis (continuous), gender (male/female), smoking status
(never/ever), duration of time between diagnosis and baseline
assessment (in years), and baseline UPDRS motor score. Subgroup
analyses were performed limited to (1) subjects with off-medication
exams only to investigate the influence of estimating missing off
exam scores from on-medications motor exam scores (excludes 83
subjects who were unable to be assessed off PD medications at
either baseline or follow-up) and limited to (2) subjects with
complete UPDRS data at both baseline and follow-up exams to
investigate the influence of replacing missing UPDRS motor exam
items as described above (excludes 26 subjects who were unable to
perform one or more motor UPDRS exam items at either baseline
or follow-up, e.g. patients unable to walk due to a missing lower
limb).
The repeat lengths of SNCA-Rep1 were analyzed in the manner
originally presented by Maraganore et al [10]: a dominant genetic
model comparing 263/263 and 263/X vs. X/X, where X is either
the 259 or the 261 allele; and a dominant genetic model
comparing 259/259 and 259/X vs. X/X, where X is either the
261 or the 263 allele. The SNCA SNP rs356165 was analyzed
under an additive (or allele dosage) genetic model similarly to prior
studies [28,30,31]. Assuming that the 59 SNCA-Rep1 and the 39
rs356165 regions represent independent contributors to genetic
risk of PD [31,36,37], and possibly also to progression of motor
symptoms, we investigated potential statistical interaction between
SNCA-Rep1 263bp allele and the rs356165 ‘G’ allele. P-values
presented are uncorrected; for multiple comparisons considera-
tions, four tests were performed and a p-value of 0.0125 was
considered the experiment-wide significance level. Sensitivity
analyses were performed to assess model robustness to additional
possible covariates and the outcome cut-point.
Results
The characteristics of PD patients in this report are summarized
in tables 1 and 2. We followed patients on average for 5.1 (std dev
2.2) years and categorized 35 (15.1%) patients as ‘‘fast progres-
sors’’ for motor symptom decline as measured by the motor
UPDRS. Fast progressors were older at time of PD diagnosis, had
a lower UPDRS motor exam score at baseline, a shorter follow-up,
and had lower baseline bradykinesia, rigidity, and tremor sub-
scores (table 2), but did not differ from slow progressors in other
risk factors including predominant motor type (akinetic [63]: 74%
and 81%, respectively; p-value=0.24). Deceased patients were
older, had a higher baseline UPDRS motor score, higher
bradykinesia and gait/balance subscores, a lower Mini Mental
State Exam (MMSE) [64], and a higher Geriatric Depression
Score (GDS) [65] than both slow and fast progressors. Participants
lost to follow-up but not deceased were not different from slow
progressors on demographics or risk factors. Neither deceased
patients nor those lost to follow-up differed from slow progressors
on SNCA-Rep1 or rs356165 genetic variants (table 3). Finally,
although carriers of the 263bp SNCA-Rep1 risk allele were on
average younger (64 years) than non-carriers (67 years) at time of
PD diagnosis, this difference was not formally statistically
significant (p.0.10).
In logistic regression analyses adjusting for age, gender,
smoking, duration of time between diagnosis and baseline
assessment, and baseline UPDRS motor score, we observed no
association between the SNCA-Rep1 259 allele and progression
under a dominant genetic model although the odds ratio is in the
expected (‘‘protective’’) direction (table 4). In contrast, PD patients
carrying at least one 263bp allele in SNCA-Rep1 exhibited 4-fold
higher odds of fast progression (OR=4.03; 95% CI: 1.57–10.4;
table 5). Separately, the G allele of SNCA rs356165 increased risk
of faster progression 60% (one copy) or 270% (two copies) under
an additive genetic model (table 6), albeit this association did not
reach statistical significance. Effect estimates were robust to
adjustment for education, minority status, PD family history,
and bradykinesia, rigidity, tremor, and gait/balance subscores.
In subgroup analyses restricted to patients with only off
medication UPDRS exams or subjects with complete UPDRS
data, the estimated effects were similar to or stronger than those
for the full study sample (tables 4, 5, 6) although the confidence
intervals were wider due to smaller sample sizes. Our results were
relatively insensitive to lowering the cut-point for fast progression
(e.g. top quartile rate of change vs. others, SNCA-Rep1 OR=2.66;
95% CI: 1.14–6.19). Finally, although we did not observe
statistical interaction, patients with the ‘GG’ risk genotype at
rs356165 and without the SNCA-Rep1 263bp risk allele exhibited
a smaller increase in risk of faster progression than patients with
the ‘GG’ risk genotype and with at least one copy of the SNCA-
Rep1 263bp risk allele; additionally, we observed a strong trend
across categories of the combined genetic variants (table 7; p-value
for trend 0.002).
Discussion
Heterogeneity in clinical presentation is widely acknowledged in
PD [8] and the rate of disease progression and motor symptom
decline is known to vary strongly [66]. The a-synuclein protein is
a major component of Lewy bodies and participates in the
molecular pathogenesis of PD. Mutations and multiplications of
the SNCA gene cause familial parkinsonism and genetic variations
are recognized as risk factors for idiopathic PD [50]. Here we
present the first evidence that SNCA is an important and strong
predictor of faster motor symptom decline in idiopathic PD: we
observed a 4-fold higher risk of PD for carriers of the SNCA-Rep1
263bp allele and, when considering both Rep1 263bp and
rs356165 ‘G’ allele, we observed a strong trend for faster motor
decline across categories of the combined genetic variants.
SNCA-Rep1 allelic variants and 39UTR variants (including
rs356165) are correlated with SNCA mRNA expression in human
a-Synuclein and Motor Symptom Progression in PD
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parkinsonism with gene duplication or triplication increased
mRNA expression has been linked to severity of disease (e.g.
younger onset, faster decline, cognitive impairment) [50]. Thus,
evidence that these PD-associated SNCA variants have functional
consequences is accumulating rapidly. In our population-based
idiopathic PD cohort, both the SNCA-Rep1 promoter and 39UTR
risk variants in combination with the promoter predicted faster
motor symptom decline and these findings suggest that a-synuclein
Table 1. Demographic characteristics of Parkinson’s disease cohort members at baseline exam (2001–2007).
Slow Progressor Fast Progressor p* Deceased p
1 Lost to Follow-up p
{
All (n) 197 35 83 44
Age at PD Diagnosis (mean6SD) 66.469.9 69.668.6 0.07 73.966.8 ,0.01 64.9613.4 0.46
Age Range of Subjects 35–88 50–83 47–88 34–84
Female (%) 40.6 48.6 0.38 47.0 0.32 40.9 0.97
Never Smokers (%) 55.8 40.0 0.08 51.8 0.54 47.7 0.33
Positive Family History of PD (%) 14.2 14.3 0.99 13.2 0.83 20.5 0.30
Non-Caucasian Race/Ethnicity (%) 18.8 22.9 0.57 18.1 0.89 20.4 0.80
,=12 year of school (%) 39.2 33.3 0.62 42.2 0.74 55.6 0.21
Abbreviations: PD = Parkinson’s disease; SD = standard deviation.
*P-value for chi-square test or t-test of fast vs. slow progressors.
1P-value for chi-square test or t-test of deceased participants vs. slow progressors.
{P-value for chi-square test or t-test of lost participants vs. slow progressors.
doi:10.1371/journal.pone.0036199.t001
Table 2. Phenotypic characteristics of Parkinson’s disease cohort members at baseline exam (2001–2007) and follow-up (2008–
2010).
Slow Progressor Fast Progressor p* Deceased p
1 Lost to Follow-up p
{
All (n) 197 35 83 44
Duration of PD prior to baseline
mean6SD (years) 1.8461.3 2.0161.6 0.50 2.0861.35 0.16 1.8861.16 0.86
range 0–7.1 0–6.7 0–4.9 0–4.5
Interval between exams
mean6SD (years) 5.2062.2 4.2662.1 0.02 n.a. n.c. n.a. n.c.
range 0.85–9.1 1.14–8.7 n.a. n.a.
Baseline UPDRS motor score
mean6SD (points) 20.569.7 15.867.5 0.01 27.0613.6 ,0.01 20.3610.5 0.89
range 4–49 3–31 5–68.6 3–51
Mean annual change in UPDRS motor score
mean6SD (points per year) 1.7361.5 6.9563.4 ,0.01 n.a. n.c. n.a. n.c.
range 0–4.94 5–24.6 n.a. n.a.
Baseline PD Subscores**
Bradykinesia (mean6SD) 6.8964.0 4.9663.4 0.01 9.3165.3 ,0.01 6.8064.3 0.89
Rigidity (mean6SD) 3.3662.4 2.4061.5 ,0.01 3.8663.1 0.19 3.4862.3 0.77
Tremor (mean6SD) 1.8061.9 1.2061.1 0.01 2.0262.3 0.45 1.3961.6 0.17
Gait/Balance (mean6SD) 2.9262.0 2.8162.1 0.78 5.1863.3 ,0.01 3.4362.6 0.23
Baseline MMSE
11 28.262.4 27.861.9 0.44 26.563.0 ,0.01 27.962.5 0.61
Baseline GDS
{{ 3.2663.4 3.3163.0 0.94 4.2562.8 0.01 3.4463.1 0.75
Abbreviations: SD = standard deviation; PD = Parkinson’s disease; yrs = years; n.a. = not applicable; n.c. = not calculated; UPDRS = Unified Parkinson’s Disease
Rating Scale; MMSE = Mini Mental State Exam; GDS = Geriatric Depression Score.
*P-value for t-test of fast vs. slow progressors.
1P-value for t-test of deceased participants vs. slow progressors.
{P-value for t-test of lost participants vs. slow progressors.
**PD subscores (bradykinesia, rigidity, tremor, gait/balance) calculated according to Louis (ref 3).
11Mini Mental State Exam score according to Folstein (ref 64).
{{Geriatric Depression Score according to Yesavage (ref 65).
doi:10.1371/journal.pone.0036199.t002
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well as with disease risk.
Apart from clinical trials of mostly younger onset patients [68–
73], and hospital-based studies of prevalent cases [4,66,74], only
three prior population-based studies conducted in New York [3],
Norway [5], and the UK [6] collected longitudinal UPDRS data
for evaluating PD motor progression. All three population-based
studies were limited by follow-up sample size (,150 subjects
remaining after 4 years or more); whereas our study has 232
subjects at on average 5.1 years of follow-up, and thus is the largest
population-based longitudinal study of PD motor symptoms in the
literature to date. Additionally, two studies [3,5] assessed only
prevalent cases with long mean duration of disease prior to
baseline (6.8–9.1 years), thus missing early stages of disease
progression, a potentially critical time for neurodegeneration of
the dopamine system [66]. Faster motor decline in early disease is
consistent with an early accelerated dopaminergic neurodegenera-
tion and an exponential demise of neurons shortly after PD onset
that levels off over time [75]. This early stage of PD might be the
most sensitive and effective period for interventions aimed at
slowing disease progression.
Our PD cohort is population-based and, thus, we expect it to
adequatelyrepresenttherangeofdiseasephenotypesandtreatment
protocolsfoundinthegeneralU.S.PDpopulation.Ourstudydesign
also ensured representativeness of our patients to idiopathic PD
patients seen in the health care system in general, different from
morecommonPDprogressionstudiesthatassembledhomogeneous
groups of very select patients from clinical trials or tertiary care
facilities.TheaverageageandagerangeofourPDpatientcohortat
diagnosis (68.3 years; range 34–88) is as expected in population
based studies of PD; and similar to what was reported in the
longitudinal study of incident PD in the UK (70.1 years; range 37–
94) [6,76], and to the age range in both prevalence progression
studies in NY (range 25–93) [3] and Norway (range 27–85) [77].
Table 3. SNCA Rep1 (D4S3481) and rs356165 genotypes of Parkinson’s disease cohort members.
Slow Progressor Fast Progressor p* Deceased p
1 Lost to Follow-up p
{
All (n) 197 35 83** 44
SNCA Rep1 genotypes, n(%)
259/259 20 (10.2) 1 (2.9) 11 (13.6) 1 (2.3)
259/261 75 (38.1) 9 (25.7) 30 (37.0) 23 (52.3)
259/263 5 (2.5) 4 (11.4) 6 (7.4) 3 (6.8)
261/261 82 (41.6) 15 (42.9) 30 (37.0) 13 (29.6)
261/263 12 (6.1) 6 (17.1) 4 (5.0) 4 (9.1)
263/263 3 (1.5) 0 (0.0) 0.01 0 (0.0) 0.33 0 (0.0) 0.12
SNCA rs356165
AA 63 (32.0) 8 (22.9) 29 (35.4) 14 (31.8)
AG 101 (51.3) 16 (45.7) 40 (48.8) 22 (50.0)
GG 33 (16.7) 11 (31.4) 0.11 13 (15.8) 0.86 8 (18.2) 0.97
Abbreviations: SNCA = alpha-synuclein.
*P-value for chi-square test of fast vs. slow progressors.
1P-value for chi-square test of deceased participants vs. slow progressors.
{P-value for chi-square test of lost participants vs. slow progressors.
**One deceased subject had a genotype of 257/259 and one subject has not been genotyped for SNCA Rep1 and rs356165.
doi:10.1371/journal.pone.0036199.t003
Table 4. Logistic regression odds ratio (and 95%CI) for faster progression
* by SNCA Rep1 genotypes defined by the 259 base pair
allele vs others (dominant model).
Primary Analysis Subgroup #1 Subgroup #2
Slow Fast OR(95%CI) p
{ Slow Fast OR(95%CI) p
{ Slow Fast OR(95%CI) p
{
Subjects (n) 197 35 125 24 174 32
259 non-carriers (%)
1 49.2 60.0 1.00(reference) 47.2 62.5 1.00(reference) 50.6 59.4 1.00(reference)
259 carriers (%)
1 50.8 40.0 0.76(0.3521.65) 52.8 37.5 0.60(0.23–1.54) 49.4 40.6 0.88(0.39–1.98)
0.486 0.286 0.753
All analyses are adjusted for age at diagnosis (continuous), gender (male/female), smoking status (never/ever), duration of time between PD diagnosis and baseline
assessment (in years), and baseline UPDRS motor score.
Abbreviations: SNCA = alpha-synuclein; OR = odds ratio; CI = confidence interval; p = p-value; n = number.
Subgroup #1, subjects with off-medication exams only.
Subgroup #2, subject with complete UPDRS data at both baseline and follow-up exams.
*Faster progression defined as $5 point change in motor UPDRS annually.
1259 non-carriers include genotypes 261/261, 261/263, or 263/263; 259 carriers include genotypes 259/259, 259/261 or 259/263.
{P-value the additive (or allele dosage) genetic model.
doi:10.1371/journal.pone.0036199.t004
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observedinourcohortofPDcasesareverysimilartothoseobserved
for PD cases in studies indexed by PDGene (www.pdgene.org [33]).
Thus, the results observed in our population-based cohort are more
likely to be generalizable to the U.S. PD population than results of
placebo arms of clinical trials that limit enrollment to a select age
range or stage of disease.
Consistent with observations from a recent longitudinal imaging
study [78] the motor symptoms of our PD patients age 66 and
younger declined at a slower rate than those of our patients age 67
and older (2.13 points/year vs. 2.80 points/year, p=0.043).
Adjusting for age demonstrated that our observed genetic
associations are independent of age. In fact, age-stratified analyses
(,=66 and .66), while underpowered, produced similar odds
ratio estimates as the combined sample.
Due to the logistics of a population based study, we were unable
to follow our patients on an annual or more regular basis, but our
average annual rate of change measure accounts for differences in
follow-up intervals. Moreover, our slow progressors were followed
for a slightly longer interval thereby somewhat minimizing the
extent to which slow progressing subjects were misclassified due to
follow-up duration, since patients are less likely to improve once
reaching a more advanced state of motor symptom decline.
Finally, analysis limited to subjects with an interval from baseline
to follow-up of 3 years or more (mean 5.82 years follow-up)
produced odds ratios similar to analyses of the full sample (e.g.
ORRep1 263=4.05, 95%CI: 1.42–11.6).
We lost a third of all patients between baseline and follow-up,
mostly because participants had died. Other population-based
studies of PD have similar or greater losses at follow-up: NY [3]
lost 45% at 4 years, Norway [5] lost 38% at 4 years, and UK [6]
48% at 6.6 years of follow-up. Of our subjects lost to follow-up,
69% had died during follow-up; this is similar to the only other
study of incident PD cases [6] where 64% of lost subjects had died
during follow-up. Relevant to our findings, when we examined the
genetic variants of SNCA in those lost due to death and lost due to
other reasons, we observed no differences from the comparison
group of slow progressors (p.0.10).
Unlike many longitudinal PD studies, we attempted to examine
all patients in a practically defined off PD medication state, but this
was not achieved in about 20% of exams. While this could have
caused non-differential outcome misclassification with regard to
genetic factors and an underestimation of the rate of progression
and the effect size, we observed an overall mean change in
UPDRS motor score of 2.52 points/year (average follow-up 5.1
years) which is very similar to the rate observed by the only other
Table 5. Logistic regression odds ratio (and 95%CI) for faster progression
* by SNCA Rep1 genotypes defined by the 263 base pair
allele vs others (dominant model).
Primary Analysis Subgroup #1 Subgroup #2
Slow Fast OR(95%CI) p
{ Slow Fast OR(95%CI) p
{ Slow Fast OR(95%CI) p
{
Subjects (n) 197 35 125 24 174 32
263 non-carriers (%)
1 89.9 71.4 1.00(reference) 92.8 66.7 1.00(reference) 89.7 68.8 1.00(reference)
263 carriers (%)
1 10.2 28.6 4.03(1.57–10.4) 7.2 33.3 9.00(2.63–30.8) 10.3 31.2 4.53(1.69–12.1)
0.004 ,0.001 0.003
All analyses are adjusted for age at diagnosis (continuous), gender (male/female), smoking status (never/ever), duration of time between PD diagnosis and baseline
assessment (in years), and baseline UPDRS motor score.
Abbreviations: SNCA = alpha-synuclein; OR = odds ratio; CI = confidence interval; p = p-value; n = number.
Subgroup #1, subjects with off-medication exams only.
Subgroup #2, subject with complete UPDRS data at both baseline and follow-up exams.
*Faster progression defined as $5 point change in motor UPDRS annually.
1263 non-carriers include genotypes 261/261, 261/259, or 259/259; 263 carriers include genotypes 263/263, 261/263 or 259/263.
{P-value the additive (or allele dosage) genetic model.
doi:10.1371/journal.pone.0036199.t005
Table 6. Logistic regression odds ratio (and 95%CI) for faster progression
* by SNCA rs356165 genotypes (additive model).
Primary Analysis Subgroup #1 Subgroup #2
Slow Fast OR(95%CI) p
1 Slow Fast OR(95%CI) p
1 Slow Fast OR(95%CI) p
1
Subjects (n) 197 35 125 24 174 32
AA (%) 32.0 22.9 1.00(reference) 27.2 25.0 1.00(reference) 31.0 18.7 1.00(reference)
AG (%) 51.3 45.7 1.66(0.96–2.88) 56.0 41.7 1.57(0.77–3.19) 52.3 46.9 1.96(1.07–3.62)
GG (%) 16.7 31.4 2.76(1.57–4.84) 16.8 33.3 2.45(1.20–4.99) 16.7 34.4 3.85(2.09–7.10)
0.071 0.201 0.027
All analyses are adjusted for age at diagnosis (continuous), gender (male/female), smoking status (never/ever), duration of time between PD diagnosis and baseline
assessment (in years), and baseline UPDRS motor score.
Abbreviations: SNCA = alpha-synuclein; OR = odds ratio; CI = confidence interval; p = p-value; n = number.
Subgroup #1, subjects with off-medication exams only.
Subgroup #2, subject with complete UPDRS data at both baseline and follow-up exams.
*Faster progression defined as $5 point change in motor UPDRS annually.
1p-value for the additive (or allele dosage) genetic model.
doi:10.1371/journal.pone.0036199.t006
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2.24 points/year (average follow-up 6.6 years) albeit this rate
represents results from ‘‘on-on’’ exams [6].
Since motor symptom severity predicts increased mortality in
PD independent of age and disease duration [79], identifying
genetic predictors of faster motor decline is critical to pinpointing
biological mechanisms as targets for therapies and identifying
patients who will most benefit from early interventions. While
replication of our results in similarly well-characterized popula-
tion-based incidence PD cohorts that have been longitudinally
followed is still needed, our findings strongly suggest that a-
synuclein and related pathogenic pathways have great promise as
potential disease modifying and therapeutic targets.
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